Unlike traditional drug development, cell therapy logistics require extremely close, integrated relationships with contract research (CRO) and manufacturing (CDMO) organizations. Due to the direct line from patient to manufacturing and back, these partners function as critical extensions of the core team to ensure timeliness and safety.

The standard CDMO business model, which charges for fermentation time, rewards maximizing equipment utilization rather than process innovation. This creates a misalignment with clients who want faster, more efficient processes. An alternative model aligns CDMO revenue with process improvements, not process duration.

As the outsourcing market becomes crowded, technical capabilities are table stakes. For smaller biotech clients, the key differentiator is now customer service. Poor service experiences are creating lasting negative impressions, making relationship management critical for CDMOs to win business from this growing segment.

Don't assume a contract manufacturer understands the unwritten context behind your designs. Often, teams provide only partial information but expect perfect results. Success hinges on treating them as a partner, sharing the 'why' and performance nuances beyond the drawing to prevent misinterpretations and build a strong relationship.

The CDMO market is segmenting, rewarding companies that specialize in complex niches like sterile filling. Rather than trying to do everything, focusing on being a world-class expert attracts clients who need specialized services, much like a patient chooses a heart surgeon over a general pharmacy for a critical procedure.

For smaller biotechs, the key to a successful CRO relationship is treating them as a genuine partner. This requires moving beyond a transactional, fear-based dynamic to one of open communication and mutual respect. Biotechs should actively solicit CRO feedback, as they possess valuable cross-industry insights and can identify sponsor-side behaviors that need to change.

A company's development approach is dictated by its business model. Startups use simple, low-cost methods for quick proof-of-concept data. Large pharma invests in robust, high-throughput systems to de-risk processes for regulatory demands. CDMOs must be flexible to serve both.

Companies often mistakenly expect their CDMO to fill strategic gaps. A CDMO's role is to execute the plan provided. Handing over an incomplete process is a 'wish,' not a tech transfer, and forces them to improvise in ways that may not align with your regulatory or commercial goals.

Founders in CPG should personally master the hands-on production of their product before outsourcing. This deep knowledge of the process is invaluable, equipping you to ask specific technical questions and properly evaluate a co-manufacturer's capabilities, ensuring quality is maintained at scale.